论文部分内容阅读
目的观察紫杉醇联合卡培他滨治疗晚期胃癌的近期疗效及安全性。方法52例经病理确诊的晚期胃癌,接受紫杉醇联合卡培他滨联合化疗。紫杉醇175 mg/m2,d1;卡培他滨2 g/m2,d1～14,21 d一周期,至少化疗2周期后按WHO标准判断疗效及毒副反应。结果入组52例患者,均可评价疗效及不良反应。完全缓解0例,部分缓解22例,病情稳定30例,有效率42.3%,疾病控制率63.4%。初治组有效率57.1%,显著高于复治组25.0%(P=0.019)。主要不良反应有骨髓抑制,胃肠道反应,末梢神经毒性,多为Ⅰ～Ⅱ度,无化疗相关性死亡。结论紫杉醇联合卡培他滨治疗晚期胃癌,疗效较好,毒性低,是晚期胃癌患者的一种选择。
Objective To observe the short-term efficacy and safety of paclitaxel plus capecitabine in the treatment of advanced gastric cancer. Methods 52 cases of advanced gastric cancer confirmed by pathology received paclitaxel combined with capecitabine combined with chemotherapy. Paclitaxel 175 mg / m2, d1; capecitabine 2 g / m2, d1 ~ 14,21 d one cycle, at least 2 cycles of chemotherapy according to WHO criteria to determine the efficacy and toxicity. Results Into the group of 52 patients, can evaluate the efficacy and adverse reactions. 0 cases were completely relieved, 22 cases were partly relieved, 30 cases were stable, the effective rate was 42.3% and disease control rate was 63.4%. The effective rate of the first treatment group was 57.1%, significantly higher than that of the second treatment group (25.0%, P = 0.019). The main adverse reactions are myelosuppression, gastrointestinal reactions, peripheral neurotoxicity, mostly Ⅰ ~ Ⅱ degrees, no chemotherapy-related deaths. Conclusion Paclitaxel combined with capecitabine in the treatment of advanced gastric cancer, with good curative effect and low toxicity, is an option for patients with advanced gastric cancer.